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Summary  The  World  Health  Organization  (WHO)  resolution  adopted  in  2010  recog-
nized  viral  hepatitis  as  a  global  health  problem.  In  April  2014,  for  the  ﬁrst  time,  the
WHO  produced  guidelines  for  the  screening,  care  and  treatment  of  persons  with  hep-
atitis  C  infections.  In  May  2014,  a  follow-up  resolution  urged  WHO  Member  States  to
develop  and  implement  a  national  strategy  for  the  prevention,  diagnosis  and  treat-
ment  of  viral  hepatitis  based  on  the  local  epidemiological  context.  Although  blood
donor  screening,  which  began  in  the  early  1990s,  has  reduced  the  spread  of  the
virus  in  the  population,  the  WHO  estimates  that  150  million  people  are  chronically
infected  with  hepatitis  C  virus  (HCV)  and  are  at  an  increased  risk  of  developing  liver
cirrhosis  and  hepatocellular  carcinoma.  In  addition,  3—4  million  people  are  infected
each  year.  HCV  treatment  is  currently  evolving  rapidly,  and  several  drugs  are  in
various  stages  of  development.
With  regard  to  the  hepatitis  B  virus  (HBV),  in  March  2015,  the  WHO  published
the  ﬁrst  guidelines  for  the  prevention,  care  and  treatment  of  persons  with  chronic
hepatitis  B  infection,  which  were  designed  to  complement  the  recent  guidelines
on  HCV.  Although  the  introduction  of  an  effective  vaccine  against  the  hepatitis  B
virus  has  reduced  the  prevalence  and  health  and  economic  impact  of  hepatitis  in
industrialized  countries,  the  WHO  estimates  that  more  than  2  billion  people  are
illioHBV-infected  and  350  m
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The state of the art
In 2010,  the  World  Health  Organization  (WHO)  res-
olution recognized  viral  hepatitis  as  a  global  health
problem  and  stressed  the  need  to  implement  mea-
sures for  its  prevention,  diagnosis  and  treatment
[1].  On  May  24th,  2014,  a  follow-up  resolution  urged
WHO Member  States  to  develop  and  implement  a
national strategy  based  on  epidemiological  data.
These measures  have  not  yet  been  implemented
in many  countries.  The  spectrum  of  viral  hepati-
tis changes  in  relation  to  the  etiological  agents  in
different  geographical  areas  of  the  world  [2].
Although the  screening  of  blood  donors,  which
started in  the  early  1990s,  has  reduced  the
spread of  hepatitis  C  virus  (HCV)  in  the  popula-
tion, the  WHO  estimates  that  150  million  people,
i.e., approximately  3%  of  the  world’s  population,
are chronically  infected  with  HCV  and  are  at  an
increased  risk  of  developing  liver  cirrhosis  and
hepatocellular carcinoma  [3].  The  incidence  of  hep-
atocellular  carcinoma  increases  in  both  sexes  with
age. In  HCV-positive  patients,  the  cumulative  risk  of
developing  hepatocellular  carcinoma  in  the  40—74
age group  is  21.6%  among  males  and  8.7%  among
females. A  gradual  increase  in  risk  was  observed
with increased  serum  levels  of  alanine  aminotrans-
ferase or  with  decreased  basal  levels  of  serum
cholesterol [4].  In  addition  to  this,  3—4  million  peo-
ple are  infected  each  year.  The  WHO  estimates
that 15  million  people  are  currently  HCV-infected
in European  countries  [5].
For the  ﬁrst  time,  the  WHO  has  produced
evidence-based  recommendations  regarding  the
screening,  care  and  treatment  of  patients  with  HCV
infection.  These  recommendations  are  intended
primarily for  decision-makers  in  the  ministries  of
health who  work  in  low  and  middle-income  coun-
tries.  These  guidelines  provide  country-speciﬁc
treatment  plans  and  treatment  programs  for  infec-
tious diseases.  The  guidelines  are  also  intended
to be  of  use  to  non-governmental  agencies  and
on  screening  for  HCV  infection  outlined  that  sero-
logical  testing  for  HCV  should  be  offered  to  people
who are  part  of  a population  with  high  HCV  preva-
lence or  who  have  a history  of  exposure/risk
behavior  (strong  recommendation,  moderate  qual-
ity of  evidence).  Tests  with  genomic  ampliﬁcation
techniques for  the  detection  of  ribonucleic  acid
are performed  immediately  after  a  positive  HCV
serological  test  for  the  diagnosis  of  chronic  HCV
infection,  and  an  assessment  is  required  before
initiating antiviral  therapy  (conditional  recommen-
dation,  very  low  quality  of  evidence)  [2].  With
regard to  the  hepatitis  B  virus  (HBV),  in  March
2015, the  WHO  published  the  ﬁrst  guidelines  for
the prevention,  care  and  treatment  of  people  liv-
ing with  chronic  HBV  infection.  These  guidelines  are
based on  a public  health  approach  to  using  antiviral
drugs  to  treat  chronic  HBV,  which  considers  feasi-
bility and  effectiveness  with  limited  resources,  for
example,  in  places  that  do  not  have  the  option  of
performing  specialized  tests,  such  as  HBV  DNA  test-
ing and  liver  biopsy  [6].  Although  the  introduction
of an  effective  vaccine  against  the  hepatitis  B  virus
(HBV) has  reduced  the  prevalence  and  the  health
and economic  impact  of  hepatitis  in  industrialized
countries [7], the  WHO  estimates  that  more  than  2
billion people  are  infected  with  the  virus  and  350
million people  are  chronic  carriers.  There  are  more
than 4  million  clinical  cases  of  acute  HBV  infec-
tion every  year.  In  low-endemic  countries,  such
as North  America  and  Northern  Europe,  the  esti-
mated  prevalence  of  HBsAg-positive  subjects  is  less
than 2%,  while  in  high-endemic  countries,  such  as
sub-Saharan  Africa  and  China,  the  prevalence  is  ≥
8%. Italy  is  among  the  countries  with  intermediate
endemicity (positivity  for  HBsAg  between  2%  and
7%) [7]. The  WHO  estimates  that  13.3  million  peo-
ple are  currently  HBV-infected  in  the  countries  of
the European  Region  [5].
High levels  of  viremia  or  an  infection  contracted
at a  young  age,  which  mostly  affects  males,  are
associated  with  an  increased  risk  of  death  or  ofhealthcare  professionals  for  deﬁning  the  elements
and services  required  for  the  treatment  of  HCV
patients. The  guidelines  are  also  helpful  for  clini-
cians  who  manage  HCV  patients.  Recommendations
d
a
reveloping  hepatocellular  carcinoma  [8,9].
The impact  of screening  programs  for  viral  hep-
titis and  HBV  vaccination,  which  have  signiﬁcantly
educed viral  hepatitis,  have  been  appreciated
HBV  and  HCV  epidemiology  
Table  1  Data  from  Hanaﬁah  et  al.  [12].
Seroprevalence  (%)  of  HCV
Africa  2.0—2.8
Americas  1.3—2.0
Asia  1.4—3.8
Europe  2.4—2.9
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that were  previously  difﬁcult  to  treat.  The  useOceania  2.6
ince  the  1990s.  Epidemiological  studies  conducted
n mortality  showed  that  increased  life  expectancy
s attributable  to  healthcare  interventions  and,
peciﬁcally,  the  introduction  of  new  drugs  as  well
s general  sanitary  improvements.  The  evolution  of
pidemiology  in  hepatology  is  most  certainly  the
verall result  of  the  introduction  of  new  treatments
especially in  recent  years)  and  the  development  of
 clinical  hepatology-oriented  approach  to  shared
uidelines.
Based  on  these  premises,  this  review  uses
ational surveys  to  examine  the  changes  in  HCV
nd HBV  epidemiology  that  are  due  to  the  intro-
uction of  screening  measures  and  the  anti-HBV
accine, with  a  view  toward  strengthening  and  pro-
oting liver  disease  stage  assessment  and  eligibility
or treatment  throughout  the  world,  particularly  in
ow- and  middle-income  countries,  based  on  the
orld Health  Organization  guidelines.
cute HCV and HBV infection
he  data  available  on  acute  viral  hepatitis  needs  to
e interpreted  with  caution  because  patients  are
ften asymptomatic.  Approximately  80%  of  people
eveloping  an  acute  HCV  infection  have  symp-
omatic disease  [9]. Similarly,  less  than  10%  of
hildren  and  30—50%  of  adults  with  acute  HBV  infec-
ion have  icteric  disease  [10,11].
There  are  two  monitoring  systems  for  acute
iral hepatitis  in  Italy:  the  Integrated  Epidemio-
ogical System  for  Acute  Viral  Hepatitis  (SEIEVA)
nd data  from  the  Italian  Association  of  Infec-
ious and  Tropical  Diseases  (SIMIT).  These  two
ystems also  estimate  the  risk  factors  associated
ith the  infections.  Notiﬁcation  shall  be  made  by
he spokespersons  of  hospitals  taking  part  in  the
onitoring  of  infected  people.
The most  effective  preventive  measures  for  HCV
urrently  include  blood  and  organ  donor  screen-
ng and  testing  (Table  1),  the  implementation  of
ractices  in  healthcare  settings  and  a  strong  edu-
ation  program.  As  the  virus  has  frequent  genetic
ariations,  no  vaccine  has  been  developed  against
CV.
o
f
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In  1992,  only  31  countries  vaccinated  infants  for
BV. This  year,  the  World  Health  Assembly  passed
 resolution  to  recommend  global  vaccination  for
BV. Vaccinations  increased  signiﬁcantly  in  2012,
hen 183  Member  States  (members  of  the  WHO  are
rouped  according  to  regional  distribution,  with  a
otal of  194  regions)  vaccinated  infants  for  HBV,  and
9% of  children  received  the  vaccination  for  HBV.
Universal immunization  from  birth  and  other  suc-
essful  HBV  vaccination  strategies  have  resulted  in
 dramatic  reduction  in  HBV  transmission  in  many
igh-endemic  countries.  This  has  led  to  a  reduction
n chronic  HBV,  liver  cirrhosis  and  hepatocellular
arcinoma,  which  have  caused  major  concerns  for
ublic health  and  the  economy  in  those  areas  [13].
able  2  shows  the  percentage  of  HBV  immuniza-
ion coverage  among  1 year  olds  in  the  WHO  region
14].
Data from  Italy  shows  a  signiﬁcant  reduction
n HBV  notiﬁcations  since  1991,  when  vaccination
ecame mandatory  for  all  newborns  and  12-year-
ld adolescents  [15].
hronic HCV and HBV infection
urveillance  for  HCV  and  HBV  chronic  liver  disease
ould provide  information  about  the  prevalence
nd burden  of  the  disease,  associated  risk  factors
nd prevention  and  treatment  strategies.  Recently,
n the  United  States  [16]  and  some  regions  of
taly, such  as  Tuscany  (Italy),  speciﬁcally  the  Health
gency of  Tuscany,  pilot  programs  were  proposed
or chronic  liver  disease,  providing  information
bout the  burden  of  the  disease,  prevention  pro-
rams and  newly  developed  therapies.
Several drugs  are  currently  available  to  treat
CV-infected patients,  and  the  cure  rates  are
ontinuously improving  because  of the  introduc-
ion of  new  drugs.  In  Europe,  currently  available
reatments for  HCV  infection  include  standard
egylated interferon  (PegINF)  and  ribavirin  (RBV),
rotease  inhibitors  (boceprevir,  telaprivir  — ﬁrst
eneration  —  and  simeprevir  —  second  genera-
ion -),  the  RNA  polymerase  inhibitor  of  HCV  NS5B
NA-dependent  (sofosbuvir)  and  NS5A  replication
omplex inhibitors  (daclatasvir).
As noted  by  the  WHO,  HCV  treatments  are
apidly evolving,  and  several  drugs  are  in  various
tages of  development.  These  new  molecules
re able  to  treat  more  than  90%  of  HCV-infected
atients and  are  effective  against  genotypesf these  agents  reduces  the  necessity  of  close
ollow-up monitoring,  the  hospitalization  rate
or adverse  effects,  the  need  for  specialist  care
392  
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nd  the  amount  of  resources  required  for  disease
rogression, including  end-stage  liver  disease,
iver cancer  and  liver  transplantation.  However,
he cost  of  a 3-month  treatment  course  of  all-oral,
irect-acting antivirals  (DAAs)  is  roughly  estimated
t between  $100  and  $270  [17].
Current  guidelines  contain  recommendations  for
ll drugs  that  were  approved  by  December  2013,
ut these  will  be  updated  periodically  with  recom-
endations  for  newly  approved  drugs  [2].
The recommendations  for  treating  HCV  infection
utlined that  persons  with  chronic  HCV  infec-
ion, including  those  who  inject  drugs,  should  be
ssessed for  antiviral  treatment  (strong  recommen-
ation,  moderate  quality  of  evidence);  treatment
ith  PegIFN  in  combination  with  RBV  is  recom-
ended for  antiviral  treatment  of  chronic  HCV
nfection  rather  than  standard  non-PegINF  with  RBV
strong recommendation,  moderate  quality  of  evi-
ence); treatment  with  the  direct-acting  antivirals
elaprevir  or  boceprevir,  administered  with  PegIFN
nd RBV,  is  suggested  for  a genotype  1  chronic
CV infection  rather  than  PegIFN  and  RBV  alone
conditional  recommendation,  moderate  quality  of
vidence); treatment  with  sofosbuvir,  administered
ith RBV  with  or  without  PegIFN  (depending  on  the
CV genotype),  is  recommended  in  genotypes  1,
, 3  and  4  HCV  infection  rather  than  PegIFN  and
BV alone  (or  no  treatment  for  persons  who  can-
ot tolerate  interferon)  (strong  recommendation,
igh quality  of  evidence);  simeprevir,  in  combi-
ation with  PegIFN  and  RBV,  is  recommended  for
ersons with  genotype  1b  HCV  infection  and  for
ersons with  genotype  1a  without  the  Q80  K poly-
orphism  rather  than  PegIFN  and  RBV  (strong
ecommendation,  high  quality  of  evidence)  [2].
everal longitudinal  studies  have  shown  that  a
ustained virological  response  is  associated  with
brosis  regression  [18,19].
The WHO  guidelines  on  HCV  have  not  yet  been
pdated with  currently  available  drugs,  such  as
aclatasvir  and  ledipasvir.
Interferon-free  therapies  are  well  tolerated  and
ffective,  but  their  high  cost  forces  clinicians  down
ore cost-effective  paths.
Regarding  HBV,  several  lines  of  evidence  sug-
est that  long-term  complete  suppression  of  HBV
eplication  by  nucleosides/nucleotides  results  in
n improved  outcome  in  the  long-term  that  signiﬁ-
antly  reduces  the  risk  of  developing  liver  cirrhosis,
epatocellular  insufﬁciency  and,  potentially,  the
isk of hepatocellular  carcinoma  [20]. Moreover, longitudinal  assessment  of  liver  ﬁbrosis  has
emonstrated a histologically  proven  regression
f liver  ﬁbrosis  during  entecavir/tenofovir  ther-
py [21]. Recent  studies  have  shown  that  HBsAg
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pBV  and  HCV  epidemiology  
uantiﬁcation  predicts  the  treatment  response  to
egINF in  chronic  patients  [22—24].
The recent  guidelines  for  HBV  prevention,  care
nd treatment  [6]  provide  a  framework  for  the
evelopment or  strengthening  of  these  HBV  pro-
rams in  low-  and  middle-income  countries,  but
hey are  also  of  relevance  to  some  high-income
ountries.
In the  non-invasive  assessment  of  the  liver
isease stage  at  baseline  and  during  follow-up,
he aspartate  aminotransferase  [AST]-to-platelet
atio index  (APRI)  is  recommended  to  assess  the
resence  of  cirrhosis  (APRI  score  >  2  in  adults)  in
ettings  with  limited  resources.  Transient  elastog-
aphy  (e.g.,  FibroScan)  or  the  FibroTest  may  be
he preferred  method  where  available  and  if  cost
s not  a  major  constraint.  (Conditional  recom-
endation, low  quality  of  evidence.)  All  adults,
dolescents and  children  with  chronic  HBV  infec-
ion and  compensated  or  decompensated  cirrhosis
or cirrhosis  based  on  APRI  score  >  2  in  adults)  should
e treated  regardless  of  their  ALT  levels,  HBeAg
tatus or  HBV  DNA  levels  (strong  recommendation,
oderate  quality  of  evidence).  Treatment  is  rec-
mmended  for  adults  with  chronic  HBV  infection
ho do  not  have  clinical  evidence  of  cirrhosis  (or
ased  on  an  APRI  score  ≤  2 in  adults)  but  who  are
ver the  age  of  30  and  have  persistently  abnor-
al ALT  levels  and  high  levels  of  HBV  replication
HBV DNA  >  20,000  IU/mL),  regardless  of  HBeAg  sta-
us (strong  recommendation,  moderate  quality  of
vidence).  Where  HBV  DNA  testing  is  not  avail-
ble, the  treatment  may  be  considered  based  on
ersistently  abnormal  ALT  levels  alone,  regardless
f HBeAg  status  (conditional  recommendation,  low
uality of  evidence).
These guidelines,  based  on  a  public  health
pproach, seek  to  ensure  the  widest  possible  access
o high-quality  services  at  the  population  level
ased  on  what  is  feasible  on  a  large  scale  in  settings
ith limited  resources.
here are we now?
urrently,  interferon-  and  ribavirin-free  treatment
egimens  are  available  and  require  shorter  treat-
ent periods  (3  months).  These  regimens  do  not
ave the  substantial  associated  side  effects,  and
reliminary  results  suggest  that  these  treatments
re also  effective  in  patients  with  decompensated
irrhosis [25].
However,  given  the  high  number  of  chronically
nfected patients  and  the  high  cost  of  these  drugs,
he new  regimens  will  be  inaccessible  to  many
atients throughout  the  world.  In  the  United  States,
t
c
a393
he  estimated  manufacturing  cost  of  12  months  of
reatment per  person  is  US$68—136  with  sofosbuvir
nd US$130—270  with  simeprevir  [26].  Sofosbuvir
nd simeprevir  were  approved  by  the  European
edicines Agency  (EMA)  for  the  antiviral  treatment
f HCV-infected  adults  in  2013.  The  price  of  sofos-
uvir is  $1000  per  400  mg  pill.  Accordingly,  the  cost
f the  sofosbuvir  component  in  a 12-week  treat-
ent course  is $84,000  (the  total  regimen  cost
epends  on  the  other  medications  used  in  combina-
ion with  sofosbuvir)  [27]. The  price  of  simeprevir
s $790  per  capsule.  The  cost  of  simeprevir  in
 12-week  supply  is  $66,360.  A  12-week  course
f simeprevir  plus  sofosbuvir  costs  approximately
150,000 [28]. Daclatasvir  was  approved  by  the  EMA
n January  2014.
In  July  2013,  the  WHO  estimated  that  over  150
illion people  are  chronically  infected  worldwide.
t is  estimated  that  12%  of  the  150  Million  HCV-
nfected people  live  in  low-,  15%  in  high-  and  73%  in
iddle-income  countries  [29]. The  5  countries  with
he highest  prevalence  of  people  with  chronic  HCV
nfection  are  China  (29.7  million),  India  (18.2  mil-
ion), Egypt  (11.8  million),  Indonesia  (9.43  million)
nd Pakistan  (9.42  million)  [29]. Gilead  has  ﬁnalized
n agreement  for  the  introduction  of  sofosbuvir
n Egypt.  It  has  offered  to  supply  the  medicine
o Egypt  at  a 99  percent  discount  of  the  U.S.
rice [30].  In  general,  access  to  new  treatments  is
xtremely difﬁcult  in  low-  and  middle-income  coun-
ries due  to  the  high  costs  and  the  complexity  of
he management  of  these  patients.  The  currently
vailable data  fails  to  clearly  estimate  the  epidemi-
logy of  chronic  HCV  infection  at different  stages  of
he disease,  but  the  preferred  strategy  is to  treat
atients  in  advanced  stages  of  chronic  HCV  infec-
ion with  newly  accessible  drugs.
As in  the  case  of  HIV/AIDS,  competition  among
everal anti-HCV  (included  INF-Free)  products  is
ikely to  bring  about  a  reduction  in  treatment  costs.
everal studies  have  shown  a sustained  virological
esponse of  up  to  100%  in  both  cirrhotic  and  non-
irrhotic  patients  and  also  in  null  responders  with
nterferon-free  regimens  [31].
Antiviral  HBV  treatment  has  improved  dramat-
cally, and  potent  agents,  such  as  tenofovir  and
ntecavir,  cause  a minimal  risk  of  resistance  [32].
nfortunately,  the  cost  of  treatment  may  be  too
igh for  the  vast  majority  of  those  living  in  low-
ncome  countries,  especially  because  most  patients
ill require  long-term  therapy  [33]. Education  and
ublic awareness  is  very  important  for  reducing  the
ransmission  of  HBV  and  its  sequelae.
HBV drugs  are  also  currently  being  trialed,  which
ompared to  the  current  nucleoside/nucleotide
nalogs,  could  induce  persistent  suppression  of
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HBV-DNA  and  cause  HBsAg  negativity  and  the
eradication of  cccDNA.  The  advantage  of  third
generation  nucleoside/nucleotide  analogs  is  viral
suppression  of  over  99%,  the  regression  of  ﬁbro-
sis, the  probability  of  HCC  reduction  (ultrasound  is
requested every  6  months),  and  tolerability  (only
2% of  patients  had  adverse  events  after  7  years  of
treatment).  The  disadvantages  include  the  unlim-
ited duration  of  treatment,  the  low  rate  of  loss
of HBsAg  and  the  seroconversion  to  anti-HBs.  With
regard to  HBV,  certain  drugs  have  been  available  for
several years;  however,  nucleosides/nucleotides
are  still  not  able  to  eradicate  cccDNA.  Indeed,  the
target of  these  drugs  is  viral  polymerase,  a multi-
functional  reverse  transcriptase.  Interferon  induces
both the  immunomodulation  and  suppression  of
cccDNA transcription.  New  drugs  are  being  tested
that target  cccDNA,  in  particular,  inhibitors  of  the
formation  of  cccDNA,  transcription  inhibitors  and
drugs that  disrupt  or  degrade  the  cccDNA.  Other
drugs still  undergoing  testing  include  translocation
inhibitors of  the  virus  in  the  cytoplasm  or  assem-
bly of  the  nucleocapsid  to  DNA  or  inhibitors  of  the
release  of  HBsAg.  Finally,  new  immunomodulators
are in  a  more  advanced  trial  stage.  Among  these
is a  vaccine  treatment  that  boosts  the  immune
response.
Agonists of  toll-like  receptors  act  on  adaptive
and innate  immunity  and  on  antiviral  cytokines
[34].  Therefore,  the  treatment  goal  would  be  a spe-
ciﬁc process  with  which  to  achieve  HBsAg  loss  and
HBV eradication.
In conclusion,  the  epidemiology  of  both  HCV  and
HBV is  changing  constantly  and  rapidly  and  requires
the support  of  policy-makers  to  promote  prevention
and treatment  programs.
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